GLP-1 Drugs and Bone Density: Fracture-Risk Evidence Reviewed (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. Do not start, stop, or change any treatment based on what you read here. Consult your doctor about bone health and weight-loss medications.

GLP-1 drugs like Ozempic, Wegovy, and Zepbound strip off weight fast. Bone is part of what changes when the weight comes off.

This review pulls the real numbers from the bone-density substudies, the fracture cohorts, and the head-to-head exercise trials. Every figure is tied to a primary source.

The short version is nuanced. Bone density can fall on a GLP-1, but the fracture data so far look reassuring, even protective in some studies.

Do GLP-1 drugs cause bone loss?

Yes, bone mineral density tends to fall during fast weight loss on a GLP-1, but the bone loss seems driven mostly by the weight loss itself, not by direct drug toxicity to bone. This is the key distinction the headlines miss.

Your skeleton adjusts to the load it carries. When you shed 15% or 20% of your body weight, the mechanical strain on your bones drops, and the body trims bone to match (Frontiers in Endocrinology, 2022).

That is true for dieting, bariatric surgery, and GLP-1 drugs alike. Any large, rapid loss of weight pulls bone density down to some degree.

So the real question is not "do GLP-1s lower bone density." It is whether they lower it more, or less, than other ways of losing the same weight.

GLP-1 receptors do appear on bone cells, and gut hormones can influence bone turnover. But most researchers think the bone changes seen in trials track with weight loss, not a poison effect on the skeleton (Journal of Endocrinology, 2025).

This is also why bone loss often runs alongside muscle loss on these drugs. Both lean tissue and bone respond to the same rapid drop in weight and load.

What does the trial evidence show on bone mineral density?

The most direct trial, a 52-week randomized study in adults at high fracture risk, found semaglutide cut hip bone density by about 2.6% and spine density by about 2.1% versus placebo. That is a real, measurable loss.

Hansen and colleagues randomized 64 adults at increased fracture risk to once-weekly semaglutide 1.0 mg or placebo. After 52 weeks, the semaglutide group lost roughly 2.6% of total-hip bone density and 2.1% at the lumbar spine (eClinicalMedicine, 2024).

For context, postmenopausal women typically lose 1% to 2% of hip bone density per year. So a single year on semaglutide can compress two to three years of normal age-related loss.

Bone resorption markers rose in that trial while formation markers did not keep pace. That imbalance is the classic signature of weight-loss-driven bone remodeling (ClinicalTrials.gov NCT04702516).

The exercise comparison sharpens the picture. In a Danish trial, liraglutide alone reduced hip and spine bone density despite weight loss, while exercise alone preserved it (JAMA Network Open, 2024).

In that study, the liraglutide group lost about 0.013 g/cm² at the hip and 0.016 g/cm² at the spine versus the exercise group. Adding exercise to the drug protected the bone.

The big phase 3 obesity trials, like the STEP program for semaglutide, confirmed the large weight loss but did not center on dedicated bone-density endpoints (NEJM, 2021). The focused bone signal comes from the smaller mechanistic trials above.

Do GLP-1 drugs increase fracture risk?

No, the larger observational and pooled trial data do not show an increase in fractures, and several studies show neutral or even LOWER fracture risk versus other diabetes drugs. This is the reassuring counterweight to the bone-density numbers.

A network meta-analysis of randomized trials, covering nearly 50,000 participants, found GLP-1 drugs were associated with lower fracture risk versus placebo and other agents (Osteoporosis International, 2018).

A large population cohort using UK primary-care records found no association between GLP-1 use and bone fractures (Calcified Tissue International / PMC, 2015).

Some data point further, toward protection. A JAMA Surgery analysis linked GLP-1 use to lower vertebral fracture risk in people with type 2 diabetes (JAMA Surgery, 2024).

A Danish nationwide cohort compared GLP-1 users to DPP-4 inhibitor users and found no increased risk of major osteoporotic fractures (Bone / PMC, 2022).

How can bone density drop while fractures do not rise? Most of this fracture data comes from people with type 2 diabetes, whose bones are often more fragile and fracture-prone at baseline (Diabetes/Metabolism Research and Reviews, 2019).

For those patients, better blood sugar and lower fall risk may outweigh a modest density dip. The catch is that these studies are short, and we lack long-term fracture data in lean, older, non-diabetic users.

How does bone loss on GLP-1s compare to bariatric surgery and dieting?

Bone loss on GLP-1 drugs sits in the middle: more than dieting alone, far less than gastric bypass. The amount of bone you lose tracks closely with how fast and how much weight comes off.

Dietary weight loss produces the smallest bone changes, often around 1% to 1.5% at the hip (J Clin Endocrinol Metab, 2016).

Roux-en-Y gastric bypass sits at the other extreme, with hip bone loss reported at 8% to 11% of pre-surgical values (Frontiers in Endocrinology, 2022).

GLP-1 drugs, with hip losses around 2% to 3% in trials, fall between those two. They cause more bone loss than gentle dieting but a fraction of what surgery does.

The fracture story splits the same way. Gastric bypass clearly raises fracture risk over 2 to 5 years, while GLP-1 cohorts have not shown that signal (Obesity Surgery, 2019).

The takeaway is simple. Slower, more controlled weight loss is gentler on bone, and pairing any method with strength training narrows the gap.

Who is most at risk for bone loss on GLP-1 drugs?

Postmenopausal women, adults over 65, people with a low starting BMI, and very rapid losers carry the most bone-health risk. These groups have less bone to spare or are losing it faster.

Postmenopausal women already lose bone each year from low estrogen. A 2% to 3% drug-related dip stacks on top of that baseline decline (eClinicalMedicine, 2024).

Older adults face the same math plus higher fall risk. A small density loss matters more when balance and reaction time are already slipping.

People with a low or normal starting BMI have a thinner safety margin. They have less fat and lean mass to lose before bone and muscle take the hit.

Very rapid losers are the fourth group. The faster the scale drops, the sharper the rise in bone-resorption markers, as the high-fracture-risk semaglutide trial showed.

If you fall into one of these buckets, that does not mean the drug is off the table. It means bone monitoring and protection deserve a real conversation with your doctor, the same way you would plan to prevent muscle loss on a GLP-1.

How can you protect bone health while on a GLP-1?

The evidence points to resistance training, adequate protein, calcium and vitamin D, and DEXA monitoring as the core protective levers. The strongest data is for exercise.

In the Danish trial, exercise alone fully preserved hip and spine bone density during weight loss, and adding exercise to the GLP-1 protected bone better than the drug alone (JAMA Network Open, 2024).

Resistance and weight-bearing training signal the skeleton to hold onto bone under load. Walking helps; lifting and impact work help more. See our notes on exercise strategies during treatment.

Protein matters because bone is a protein scaffold mineralized with calcium. Most obesity-medicine clinicians target higher protein during rapid loss, though exact gram targets are individual.

Calcium and vitamin D give the raw materials and help calcium absorb. Many adults on these drugs eat less overall, so intake can quietly fall short.

Monitoring closes the loop. A baseline DEXA scan and a repeat after major weight loss can flag a problem early, especially for the higher-risk groups above. None of this is a dosing prescription; it is the pattern the evidence supports.

<a id="bone-table"></a>

Bone-density and fracture evidence at a glance

Study (author, year)	Drug	Population	Bone / fracture outcome
Hansen et al., eClinicalMedicine 2024	Semaglutide 1.0 mg	64 adults at high fracture risk	~2.6% hip and ~2.1% spine BMD loss vs placebo at 52 wk
Jensen et al., JAMA Network Open 2024	Liraglutide	195 adults with obesity, no diabetes	Liraglutide lowered hip/spine BMD; exercise preserved it
Zhang et al., Osteoporosis Int 2018	GLP-1 class (network MA)	~49,600 in RCTs	Lower fracture risk vs placebo/other agents
UK CPRD cohort, PMC 2015	GLP-1 class	216,816 type 2 diabetes patients	No association with bone fracture
Danish nationwide cohort, Bone 2022	GLP-1 vs DPP-4	National registry, type 2 diabetes	No increased major osteoporotic fracture risk
JAMA Surgery analysis, 2024	GLP-1 class	Type 2 diabetes	Lower vertebral fracture risk
Zibellini et al., JCEM 2016	Diet / surgery / drugs	Meta-analysis, obesity	Diet ~1-1.5% hip loss; bypass 8-11% hip loss

The bottom line

GLP-1 drugs can lower bone mineral density, with hip losses around 2% to 3% in the most direct trials. That loss tracks the weight you lose, not a toxic hit to the skeleton.

But the fracture data is the part that should ease worry. Large cohorts show neutral, and sometimes lower, fracture risk than other diabetes drugs.

The smart move is to protect the downside you can control. Lift weights, eat enough protein, cover calcium and vitamin D, and ask about a DEXA scan if you are postmenopausal, older, lean, or losing fast. Talk it through with your doctor before changing anything.

Related Reading

• Ozempic and muscle loss: what the research actually shows
• How to prevent muscle loss on GLP-1 medications
• Best exercise strategies on tirzepatide

Frequently asked questions

Does Ozempic cause bone loss?

Some bone-density loss is expected during rapid weight loss on semaglutide, the drug in Ozempic and Wegovy. One 52-week trial in high-risk adults found about a 2.6% drop in hip bone density versus placebo. The loss appears tied to the weight you lose, and large studies have not shown a matching rise in fractures.

Do GLP-1 drugs increase fracture risk?

The larger evidence does not show an increase. A network meta-analysis of nearly 50,000 trial participants and several national cohort studies found neutral or even lower fracture risk for GLP-1 users versus other diabetes drugs. Most of that data is in people with type 2 diabetes, and long-term data in lean, older users is still limited.

How much bone density do you lose on a GLP-1?

In the most direct trials, hip bone density fell roughly 2% to 3% over about a year. That is more than dieting alone, which causes around 1% to 1.5%, but far less than gastric bypass, which can drop hip density 8% to 11%.

Can exercise prevent bone loss on weight-loss drugs?

The evidence is strong for exercise. In a Danish randomized trial, exercise alone preserved hip and spine bone density during weight loss, and adding exercise to the drug protected bone better than the drug by itself. Resistance and weight-bearing training are the key types.

Should I get a bone density scan before starting a GLP-1?

That is a reasonable conversation to have with your doctor, especially if you are postmenopausal, over 65, have a low BMI, or expect rapid weight loss. A baseline DEXA scan and a repeat after major weight loss can catch a problem early. This is general information, not a personal recommendation.

-- The GLP-1 Daily Team